Table 1

Characteristics of the included studies

Author, year; country	Sample size*	Study period	Type of surgery	Surgical approach	Injection site	Tracer used and dose	Time between injection and detection	SLN ultrastaging
Kleppe et al25 2014; Netherlands	5	October 2012 to June 2014	PSS	LPT	UO and IP ligaments	0.2–0.5 mL of Tc-99m albumin nanocolloid and blue dye (each injection)	15 min	Yes
Hassanzadeh et al26 2016; Iran	13	January 2010 to October 2014	PSS	LPT	UO and IP ligaments (n=10); Cortex (n=3)	0.2 mL of Tc-99 m phytate+blue dye (each injection)	10 min	NS
Angelucci et al28 2016; Italy	5	April 2016 to May 2016	PSS	MIS	Hilum of ovary	0.5–1 mL of ICG, (1.25 mg/mL)	2 min	NS
Buda et al31 2017; Italy	7	NR	PSS	MIS	UO and IP ligaments	0.5 to 1 mL of ICG (1.25 mg/mL)	Real time	NS
Uccella et al23 2019; Italy	31	March 2018 - ongoing	PSS and DSS	MIS	UO and IP ligaments (after adnexectomy)	2 mL of ICG (1.25 mg/mL)	5–20 min	Yes
Lago et al24 2018; Spain	10	March 2017 to February 2018	PSS and DSS	MIS+LPT	UO and IP ligaments (after adnexectomy)	0.2 mL of Tc-99m albumin colloid (37 MBq) + 0.5 mL of ICG (1.25 mg/mL)	15 min	Yes
Lago et al30 2020; Spain	20	March 2018 to July 2019	PSS and DSS	MIS+LPT	UO and IP ligaments (after adnexectomy)	0.2 mL of Tc-99m albumin colloid (37 MBq) + 0.5 mL of ICG (1.25 mg/mL)	15 min	Yes†
Laven et al29 2021; Netherlands	11	NR	PSS and DSS	LPT	UO and IP ligaments (after adnexectomy)	0.15 mL of Tc-99m albumin nanocolloid (20 MBq) + 0.2 mL blue dye	15 min	Yes
Guerra27 2021; Venezuela	28	June 2016 to November 2019	DSS	LPT	UO and IP ligaments	0.5 mL of Isosulfan (UO ligament) + 2 mL (IP ligament)	15 min	NS

*Refers only to patients with malignant ovarian cancer.
†Ultrastaging protocol was applied a second time.40
DSS, delayed or restaging surgery; ICG, indocyanine green; IP, Infundibulo-pelvic; LPT, laparotomy; MIS, minimal invasive surgery; NR, not reported; NS, not specified; PSS, primary staging surgery; SLN, sentinel lymph node; UO, utero-ovarian.